Oncolytics Biotech Inc. — FY2021 Form 20-F
Reporting period: Fiscal year ended December 31, 2021; audited consolidated financial statements prepared under IFRS and presented in Canadian dollars unless otherwise noted. This is an annual report, not a standalone fourth-quarter filing.
Business context
Oncolytics is a development-stage biopharmaceutical company focused on pelareorep, an intravenously administered oncolytic reovirus being studied for cancer treatment. It has no product approved for commercial sale and reports no operating revenue sufficient to offset its research and development costs. Its principal near-term clinical focus is HR+/HER2-negative metastatic breast cancer, with additional studies in breast and gastrointestinal cancers.
Financial and operating results
| Metric (CAD, unless noted) | FY2021 / Dec. 31, 2021 | FY2020 / Dec. 31, 2020 |
|---|---|---|
| Revenue | No operating revenue reported | No operating revenue reported |
| Research and development expense | $12.92 million | $12.94 million |
| Operating expense | $13.31 million | $12.51 million |
| Net loss | $26.30 million | $22.51 million |
| Basic and diluted loss per share | $0.49 | $0.56 |
| Cash used in operating activities | $22.43 million | $22.07 million |
| Cash and cash equivalents | $41.26 million | $31.22 million |
| Total assets | $45.88 million | $34.35 million |
| Total liabilities | $9.78 million | $9.59 million |
| Shareholders’ equity | $36.10 million | $24.75 million |
The filing does not present meaningful revenue margins for this pre-commercial company. It reported no long-term debt; lease liabilities were $0.65 million. Current assets were $44.90 million and current liabilities were $2.69 million. A $6.73 million non-current contract liability related to the Adlai licensing agreement remained unchanged, with no revenue recognized against it in 2021.
Material changes versus FY2020
- Net loss increased by approximately $3.80 million, although loss per share narrowed as the weighted-average share count increased to 53.51 million from 40.34 million.
- Operating expenses rose approximately $0.80 million; research and development expense was broadly unchanged.
- Cash increased by approximately $10.04 million. Financing activities provided $33.02 million, primarily from ATM share sales, while operating activities used $22.43 million.
- Year-end common shares outstanding increased to 55.04 million from 46.17 million. The company issued 8.40 million shares through ATM agreements in 2021 and received $32.91 million net cash from ATM distributions.
Outlook, developments and risks
- Management expects significant losses to continue in 2022 and the foreseeable future. The filing does not give a quantified revenue or earnings forecast and states that additional financing may be needed.
- Management’s stated priority is advancing HR+/HER2-negative metastatic breast cancer toward a Phase 3, licensing-enabling study. In 2021, BRACELET-1 enrollment continued; GOBLET began enrolling; and the AWARE-1 study reported biomarker results. In AWARE-1, 60% of patients receiving pelareorep plus atezolizumab had a greater-than-30% increase in CelTIL score, the study’s stated primary endpoint measure. These are clinical findings, not regulatory approval or proof of commercial efficacy.
- The company reported $21.52 million of commitments for clinical trial, manufacturing and translational science activities expected over the next three years. It also disclosed a February 2022 non-refundable manufacturer deposit of US$1.37 million, paid after year-end and therefore not recorded as a 2021 liability.
- Key risks include clinical trial failure or delay, reliance on third-party manufacturers and CROs, access to partner checkpoint inhibitors, potential need for further capital and shareholder dilution, and COVID-19-related enrollment or supply-chain disruption. Management said the pandemic had affected trial timing and supply activities but had not significantly affected the business to date.
- The Adlai agreement grants exclusive regional rights in China, Hong Kong, Macau, Singapore, South Korea and Taiwan; potential milestone and royalty proceeds depend on development and commercialization by Adlai. The company also believes it was a PFIC for 2021, which may have adverse U.S. tax consequences for U.S. shareholders.
- Ernst & Young issued unqualified audit opinions on the financial statements and internal control over financial reporting; the auditor reported no critical audit matters. Management reported effective disclosure controls and financial reporting controls.
Important facts for investors to verify
- Current cash balance and the rate of operating cash use against management’s planned clinical and manufacturing spending.
- Progress, enrollment, timing and full results of BRACELET-1, GOBLET and other trials, including whether breast cancer findings support a Phase 3 study.
- ATM capacity remaining, subsequent share issuance and the potential dilution from outstanding options and warrants.
- Timing and funding of the $21.52 million commitments, manufacturing supply continuity, and the status of the post-year-end manufacturer agreement.
- Whether Adlai achieves development milestones and whether U.S. investors should obtain tax advice regarding PFIC status and reporting.